| Document Date: 2013-08-22 09:57:29
Open Document File Size: 194,00 KBShare Result on Facebook
City Markov / / Company Bayer / Evidence Review Group / / Currency GBP / / IndustryTerm technology appraisal guidance / technology appraisals guidance / technology appraisal / / MedicalCondition symptomatic recurrent venous thromboembolism / recurrent deep vein thrombosis / deep vein thrombosis / cancer / clinically significant liver disease / venous thromboembolism / headache / nasopharyngitis / acute symptomatic deep vein thrombosis / pulmonary embolism / Pulmonary embolisms / acute deep vein thrombosis / high blood pressure / thrombosis / chronic / liver disease / both fatal and non-fatal pulmonary embolism / symptomatic / recurrent venous thromboembolism / syndrome / nosebleed / symptomatic deep vein thrombosis / pulmonary hypertension / / MedicalTreatment surgery / / Organization NHS / Centre for Health Technology Evaluation / Appraisal Committee / / Position treating physician / Major / Executive / nurse / / Product vitamin K / Ext / / Technology 3 2 The technology / 261 2 The technology / / URL www.evidence.nhs.uk / /
SocialTag |
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism